1) elastosis solaris sun damaged skin 2) vitiligo white spot disease
Conditions
Interventions
Sponsors
Universitair Medisch Centrum Utrecht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Group I and II: adult, male or female, aged 18 years or over; patients with skin phototype VI and vitiligo; the patient must be willing and able to give written informed consent. Group I specifically: chronic vitiligo, persistant for 10 years or more, localised on sunexposed skin. Group II specifically: it must be technically possible to determine the minimal erythemal dose.
Exclusion criteria
Exclusion criteria: sunlight allergy; tendency to hypertrophic scar or keloid formation; history of alcohol or drug abuse; treatment with phototherapy or systemic (immunosuppressive) therapy such as oral steroids and cyclosporin A during the study, or within 24 weeks prior to the study; treatment with oral and local antibiotics; treatment with topical steroids or tar in the tested locations during the last 2 weeks; clinically relevant cardiovascular, gastrointestinal, liver or renal disease and/or unstable metabolic or endocrine disorders; acute or chronic local bacterial, viral or fungal diseases; women of childbearing potential not using reliable contraception; pregnancy or breast feeding; psychiatric disease or history of noncompliance which, in the investigator*s assessment would interfere with appropriate protocol treatment and monitoring.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| (a) Qualitative comparison of extra cellular matrix damage in longstanding sun exposed vitiligenous skin and adjacent normal skin using standard haematoxylin eosin and Elastica von Gieson staining procedures. (b) Quantitative comparison of infiltrating neutrophils in vitiligenous and adjacent normal skin following exposure to an equal physical dose of SSR. (c) Determining the distribution of DNA photoproducts in vitiligenous and adjacent normal skin following exposure to SSR. (d) Determining the MED of Vitiligenous skin. | — |
Secondary
| Measure | Time frame |
|---|---|
| (a) Quantitative comparison of photoaging associated proteolytic and/or neutrophil associated enzymes and cytokines: MMP-1, MMP-3, MMP-8, MMP-9, Neutrophil elastase and IL-10 in irradiated vitiligenous and adjacent normal skin. (b) Measurement of surface markers of activation on infiltrating neutrophils: CD11b, CD66b, CD63. (c) Comparison of keratinocyte activation and keratinocyte apoptosis in vitiligenous and adjacent normal skin following exposure to SSR. | — |
Countries
Netherlands
Outcome results
None listed